My friend and colleague Sue Nemetz is President of The NemetzGroup, a life sciences commercial and strategy advisory firm. Recently, TNG published a fascinating newsletter about rare diseases and the development of medicines to treat them.
“Rare diseases (AKA, ‘orphan diseases’) are unlike any other. For a host of reasons — not the least of which is the human toll these take on those afflicted and their families — the discovery, development, and commercialization of medicines in this area needs to be approached in ways that are different than what one might do with more established diseases affecting much larger populations.”
Read the entire piece here.